EUVIMEDEUVIMED entdecken
Crossref

Quantifying cost-savings in the treatment of neovascular age-related macular degeneration in Aotearoa New Zealand

James S Lewis, Matthew Roskruge, John Ah-Chan

New Zealand Medical Journal · 2024

DOI: 10.26635/6965.6533 ↗

Kurz gefasst

Fachartikel in der Zeitschrift New Zealand Medical Journal, 2024. Verfasst von James S Lewis und 2 weiteren Autor:innen. Beteiligte Einrichtung: Registrar, Department of Ophthalmology, Palmerston North Hospital, Te Whatu Ora Te Pae Hauora o Ruahine o Tararua MidCentral, Manawatū-Whanganui, New…. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Intravitreal Injections, Receptors, Vascular Endothelial Growth Factor, Angiogenesis Inhibitors.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

aims: To estimate the cost-impact if faricimab were approved for the treatment of neovascular age-related macular degeneration (nAMD) in New Zealand. methods: A retrospective, single-centre cost-analysis study. Data on intravitreal agent and injection intervals were obtained and statistically compared. Cost estimates were based on internal facility and publicly available data. The current costs of care were compared to two scenarios: one where all eyes receive faricimab, and another where eyes receiving aflibercept switch to faricimab. results: A total of 352 eyes from 292 patients were analysed. Present values locally over 10 years were estimated at -$6,776,340 for the first scenario and $5,015,922 for the second, releasing 252 and 176 hours of clinical time per year, respectively. Nationally, the savings extrapolated to -$187,925,737 and $139,104,706, respectively. The analysis indicates significant direct cost savings for the health sector and potential reductions in patient harm due to fewer injections. conclusions: The approval of faricimab for the treatment of nAMD could result in substantial direct cost savings for the health sector. Additional benefits include reducing patient harm and improving ophthalmic health inequalities for Māori and Pacific peoples. Further research in diverse patient populations across multiple centres is needed to estimate the magnitude of cost savings more accurately. This study highlights the potential of faricimab to alleviate the treatment burden and provide a more sustainable healthcare option for nAMD in New Zealand, especially in cases of recalcitrant nAMD, if used in a tailored and patient-specific manner alongside the existing armamentarium of treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Recombinant Fusion ProteinsIntravitreal InjectionsReceptors, Vascular Endothelial Growth FactorAngiogenesis InhibitorsHumansNew ZealandRetrospective StudiesMaleFemaleAgedCost SavingsMacular DegenerationAged, 80 and overCost-Benefit AnalysisWet Macular Degeneration

Substanzen

afliberceptRecombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Registrar, Department of Ophthalmology, Palmerston North Hospital, Te Whatu Ora Te Pae Hauora o Ruahine o Tararua MidCentral, Manawatū-Whanganui, New Zealand.
  • Associate Dean; Māori, Massey Business School, Massey University, Albany, New Zealand.
  • Consultant, Department of Ophthalmology, Palmerston North Hospital, Te Whatu Ora Te Pae Hauora o Ruahine o Tararua MidCentral, Manawatū-Whanganui, New Zealand.

Zitieren

APA

Lewis, J. S., Roskruge, M., & Ah-Chan, J. (2024). Quantifying cost-savings in the treatment of neovascular age-related macular degeneration in Aotearoa New Zealand. New Zealand Medical Journal. https://doi.org/10.26635/6965.6533

Vancouver

Lewis JS, Roskruge M, Ah-Chan J. Quantifying cost-savings in the treatment of neovascular age-related macular degeneration in Aotearoa New Zealand. New Zealand Medical Journal. 2024. doi:10.26635/6965.6533

BibTeX
@article{Lewis2024,
  author = {Lewis, James S and Roskruge, Matthew and Ah-Chan, John},
  title = {Quantifying cost-savings in the treatment of neovascular age-related macular degeneration in Aotearoa New Zealand},
  journal = {New Zealand Medical Journal},
  year = {2024},
  doi = {10.26635/6965.6533}
}
Kostenlos starten →